European researchers tracked 1,473 adults for up to 16 years and discovered that lower blood levels of butyrylcarnitine—a molecule crucial for mitochondrial fatty acid metabolism—predicted COPD development in people who never smoked. The comprehensive metabolomic screening identified this mitochondrial pathway as an independent risk factor, separate from established smoking-related mechanisms. This finding suggests energy metabolism dysfunction may precede lung disease by years, even without tobacco exposure. The discovery fills a critical knowledge gap, as most COPD research focuses on smoking damage rather than metabolic predisposition. Mitochondrial dysfunction has emerged as a key aging mechanism across multiple diseases, and this study positions it as a potential early intervention target for respiratory health. The prospective design strengthens causal inference compared to cross-sectional studies, though the observational nature cannot definitively prove causation. As an unreviewed preprint, these results require peer validation and replication in diverse populations. The work represents meaningful progress in understanding non-smoking COPD pathways, potentially opening avenues for metabolic interventions like carnitine supplementation or mitochondrial-targeted therapies before irreversible lung damage occurs.